These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22849701)

  • 1. Potential for statins in the chemoprevention and management of hepatocellular carcinoma.
    Lonardo A; Loria P
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1654-64. PubMed ID: 22849701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleiotropic effects of statins in the diseases of the liver.
    Janicko M; Drazilova S; Pella D; Fedacko J; Jarcuska P
    World J Gastroenterol; 2016 Jul; 22(27):6201-13. PubMed ID: 27468210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
    Goh MJ; Sinn DH
    Clin Mol Hepatol; 2022 Jul; 28(3):380-395. PubMed ID: 35021597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Sharpton SR; Loomba R
    Hepatology; 2023 Dec; 78(6):1896-1906. PubMed ID: 37013380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor.
    Sutter AP; Maaser K; Höpfner M; Huether A; Schuppan D; Scherübl H
    J Hepatol; 2005 Nov; 43(5):808-16. PubMed ID: 16083991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of Hepatocellular Carcinoma by Statins: Clinical Evidence and Plausible Mechanisms.
    Kim G; Kang ES
    Semin Liver Dis; 2019 May; 39(2):141-152. PubMed ID: 30912095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin and aspirin for prevention of hepatocellular carcinoma: what are the levels of evidence?
    Carrat F
    Clin Res Hepatol Gastroenterol; 2014 Feb; 38(1):9-11. PubMed ID: 24183917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects.
    Vargas JI; Arrese M; Shah VH; Arab JP
    Curr Gastroenterol Rep; 2017 Sep; 19(9):43. PubMed ID: 28752475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advances and controversies of statins application in prevention and treatment of hepatocellular carcinoma].
    Xu Y; Xiao P; Ba TT; Ding MM; Gao YH
    Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):751-755. PubMed ID: 34289568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.
    Kawata S; Yamasaki E; Nagase T; Inui Y; Ito N; Matsuda Y; Inada M; Tamura S; Noda S; Imai Y; Matsuzawa Y
    Br J Cancer; 2001 Apr; 84(7):886-91. PubMed ID: 11286466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma.
    Bishayee A; Politis T; Darvesh AS
    Cancer Treat Rev; 2010 Feb; 36(1):43-53. PubMed ID: 19910122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins and primary liver cancer: a meta-analysis of observational studies.
    Pradelli D; Soranna D; Scotti L; Zambon A; Catapano A; Mancia G; La Vecchia C; Corrao G
    Eur J Cancer Prev; 2013 May; 22(3):229-34. PubMed ID: 23010949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins in Chronic Liver Disease: Review of the Literature and Future Role.
    Pham N; Benhammou JN
    Semin Liver Dis; 2024 May; 44(2):191-208. PubMed ID: 38701856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug insight: statins and gastrointestinal cancer.
    Bhuket TP; Higgins PD
    Nat Clin Pract Gastroenterol Hepatol; 2006 Oct; 3(10):552-62. PubMed ID: 17008925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma.
    Montero J; Morales A; Llacuna L; Lluis JM; Terrones O; Basañez G; Antonsson B; Prieto J; García-Ruiz C; Colell A; Fernández-Checa JC
    Cancer Res; 2008 Jul; 68(13):5246-56. PubMed ID: 18593925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
    Kah J; Wüstenberg A; Keller AD; Sirma H; Montalbano R; Ocker M; Volz T; Dandri M; Tiegs G; Sass G
    Oncol Rep; 2012 Sep; 28(3):1077-83. PubMed ID: 22710979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy insight: Potential of statins for cancer chemoprevention and therapy.
    Katz MS
    Nat Clin Pract Oncol; 2005 Feb; 2(2):82-9. PubMed ID: 16264880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma.
    Wang Y; Wang W; Wang M; Shi J; Jia X; Dang S
    Can J Gastroenterol Hepatol; 2022; 2022():5389044. PubMed ID: 35356132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Causes of and prevention strategies for hepatocellular carcinoma.
    Cabibbo G; Maida M; Genco C; Antonucci M; Cammà C
    Semin Oncol; 2012 Aug; 39(4):374-83. PubMed ID: 22846856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins in liver disease: a molehill, an iceberg, or neither?
    Argo CK; Loria P; Caldwell SH; Lonardo A
    Hepatology; 2008 Aug; 48(2):662-9. PubMed ID: 18666246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.